Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight

Until 2007, paroxysmal nocturnal hemoglobinuria (PNH) was a life-threatening disorder with limited therapeutic options for controlling hemolysis and thrombosis, the latter being a major contributor to mortality. The treatment landscape underwent a significant transformation with the introduction of the anti-C5 complement inhibitor eculizumab, which substantially reduced hemolysis, lowered transfusion requirements, and, importantly, decreased the risk of thrombosis.